Cargando…

Preclinical and clinical issues in Alzheimer's disease drug research and development

Detalles Bibliográficos
Autores principales:	Mancuso, Cesare, Gaetani, Silvana
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2014
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4211396/ https://www.ncbi.nlm.nih.gov/pubmed/25389404 http://dx.doi.org/10.3389/fphar.2014.00234

Ejemplares similares

Editorial: Alzheimer’s Disease: Original Mechanisms and Translational Impact
por: Mancuso, Cesare, et al.
Publicado: (2020)

PBPK-PD modeling for the preclinical development and clinical translation of tau antibodies for Alzheimer’s disease
por: Bloomingdale, Peter, et al.
Publicado: (2022)

Pharmacological Treatment of Depression in Alzheimer’s Disease: A Challenging Task
por: Cassano, Tommaso, et al.
Publicado: (2019)

The impact of heme oxygenase-2 on pharmacological research: A bibliometric analysis and beyond
por: Mancuso, Cesare
Publicado: (2023)

Neuroprotective Potentials of Panax Ginseng Against Alzheimer’s Disease: A Review of Preclinical and Clinical Evidences
por: Li, Jing, et al.
Publicado: (2021)

Drug Development in Alzheimer’s Disease: The Contribution of PET and SPECT
por: Declercq, Lieven D., et al.
Publicado: (2016)

Preclinical Research of Dihydromyricetin for Brain Aging and Neurodegenerative Diseases
por: Martínez-Coria, Hilda, et al.
Publicado: (2019)

Prevention approaches in a preclinical canine model of Alzheimer’s disease: benefits and challenges
por: Davis, Paulina R., et al.
Publicado: (2014)

Cell-Penetrating Peptides in Diagnosis and Treatment of Human Diseases: From Preclinical Research to Clinical Application
por: Xie, Jing, et al.
Publicado: (2020)

Editorial: Model-informed decision making in the preclinical stages of pharmaceutical research and development
por: Li, Rui, et al.
Publicado: (2023)

Key factors which concur to the correct therapeutic evaluation of herbal products in free radical-induced diseases
por: Mancuso, Cesare
Publicado: (2015)

Frontiers in Drug Research and Development for Inflammatory Bowel Disease
por: Currò, Diego, et al.
Publicado: (2017)

Indian Medicinal Plants and Formulations and Their Potential Against COVID-19–Preclinical and Clinical Research
por: Ahmad, Sayeed, et al.
Publicado: (2021)

Research advances in treatment methods and drug development for rare diseases
por: Han, Qiaoqiao, et al.
Publicado: (2022)

From Autism to Eating Disorders and More: The Role of Oxytocin in Neuropsychiatric Disorders
por: Romano, Adele, et al.
Publicado: (2016)

Central mechanisms mediating the hypophagic effects of oleoylethanolamide and N-acylphosphatidylethanolamines: different lipid signals?
por: Romano, Adele, et al.
Publicado: (2015)

Effects of bariatric surgery on drug pharmacokinetics—Preclinical studies
por: Mercado, Angela, et al.
Publicado: (2023)

Therapeutic Effects of Natural Drugs on Alzheimer’s Disease
por: Ma, Yuan, et al.
Publicado: (2019)

Yuan-Hu Zhi Tong Prescription Mitigates Tau Pathology and Alleviates Memory Deficiency in the Preclinical Models of Alzheimer’s Disease
por: Iyaswamy, A., et al.
Publicado: (2020)

Preclinical evidence and possible mechanisms of β-asarone for rats and mice with Alzheimer’s disease: A systematic review and meta-analysis
por: Du, Xin-Yuan, et al.
Publicado: (2022)

The Ontogeny of Cytochrome P450 Enzyme Activity and Protein Abundance in Conventional Pigs in Support of Preclinical Pediatric Drug Research
por: Millecam, Joske, et al.
Publicado: (2018)

Editorial: The practical implication of clinical pharmacokinetics in drug development, pharmaceutical analysis, and clinical research
por: Khan, Abad, et al.
Publicado: (2023)

Preclinical Neuropathic Pain Assessment; the Importance of Translatability and Bidirectional Research
por: Fisher, Amy S., et al.
Publicado: (2021)

Icariin and Its Metabolites as Potential Protective Phytochemicals Against Alzheimer’s Disease
por: Angeloni, Cristina, et al.
Publicado: (2019)

Single-Target Versus Multi-Target Drugs Versus Combinations of Drugs With Multiple Targets: Preclinical and Clinical Evidence for the Treatment or Prevention of Epilepsy
por: Löscher, Wolfgang
Publicado: (2021)

Editorial: Pharmacology of autoimmune and neuroinflammatory disease from a preclinical and clinical perspective
por: Šíma, Martin, et al.
Publicado: (2023)

Therapeutic drug repositioning with special emphasis on neurodegenerative diseases: Threats and issues
por: Kakoti, Bibhuti Bhusan, et al.
Publicado: (2022)

Alzheimer’s disease and neuroinflammation: will new drugs in clinical trials pave the way to a multi-target therapy?
por: Melchiorri, Daniela, et al.
Publicado: (2023)

The Use of Antipsychotic Drugs for Treating Behavioral Symptoms in Alzheimer’s Disease
por: Calsolaro, Valeria, et al.
Publicado: (2019)

Trilateral association of autophagy, mTOR and Alzheimer’s disease: Potential pathway in the development for Alzheimer’s disease therapy
por: Subramanian, Arunkumar, et al.
Publicado: (2022)

HIF-1 signalling pathway was identified as a potential new pathway for Icariin’s treatment against Alzheimer’s disease based on preclinical evidence and bioinformatics
por: You, Mingyao, et al.
Publicado: (2022)

Phytochemicals in the treatment of inflammation-associated diseases: the journey from preclinical trials to clinical practice
por: Nisar, Akib, et al.
Publicado: (2023)

Pharmacological models in Alzheimer's disease research
por: Gilles, Christian, et al.
Publicado: (2000)

The discovery of rivaroxaban: translating preclinical assessments into clinical practice
por: Kubitza, Dagmar, et al.
Publicado: (2013)

Preclinical and Clinical Assessment of Cannabinoids as Anti-Cancer Agents
por: Ladin, Daniel A., et al.
Publicado: (2016)

Phytosterols: From Preclinical Evidence to Potential Clinical Applications
por: Salehi, Bahare, et al.
Publicado: (2021)

Biomarker-Drug and Liquid Biopsy Co-development for Disease Staging and Targeted Therapy: Cornerstones for Alzheimer’s Precision Medicine and Pharmacology
por: Hampel, Harald, et al.
Publicado: (2019)

Exploring the Multi–Target Neuroprotective Chemical Space of Benzofuran Scaffolds: A New Strategy in Drug Development for Alzheimer’s Disease
por: Cabrera-Pardo, Jaime R., et al.
Publicado: (2020)

Preclinical Animal Models for Dravet Syndrome: Seizure Phenotypes, Comorbidities and Drug Screening
por: Griffin, Aliesha, et al.
Publicado: (2018)

One for All? Hitting Multiple Alzheimer's Disease Targets with One Drug
por: Hughes, Rebecca E., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_v4m7pvj2njo09s1lhupe70ble1